Update of the drug resistance mutations in HIV-1: December 2009

Update of the drug resistance mutations in HIV-1: December 2009.
Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD.

Top HIV Med. 2009 Dec;17(5):138-45.

This December 2009 version of the International AIDS Society–USA (IAS–USA) drug resistance mutations list updates the figures last published in December 2008 (Johnson VA et al, Top HIV Med, 2008;16:138-145). This update includes 3 new mutations—K65R for stavudine (Hawkins CA et al, JAIDS, 2009;52:228- 234 and Wallis C et al, JAIDS, October 2009; Epub ahead of print) and K101P for efavirenz and nevirapine (Parkin NT et al, Antimicrob Agents Chemother, 2006;50:351-354; Rhee SY et al, Antimicrob Agents Chemother, 2004:48:3122-3126; and Rhee SY et al, Proc Natl Acad Sci USA, 2006;46:17355-17360). In addition, the darunavir I47V mutation and the lopinavir/ritonavir L76V mutation designations were changed to boldface to indicate their recognition as major rather than minor mutations. One mutation, L33F for tipranavir/ritonavir, was changed from a major mutation to that of a minor to reflect recent information.
Also, many of the user notes were substantially revised.